Aditxt and its wholly owned subsidiary, Ignite Proteomics, announced that Ignite has entered into a definitive business combination agreement with a strategic counterparty that is expected to result in Ignite becoming an independent publicly traded company. The transaction assigns Ignite an implied equity valuation of approximately $150 million, subject to the terms and conditions of the agreement.
Upon completion of the transaction, Ignite is expected to separate from Aditxt and operate through a newly formed public holding company, anticipated to be named Ignite Proteomics, Inc. The new entity is expected to list its common stock and public warrants on the New York Stock Exchange, subject to regulatory approvals and customary closing conditions.
Aditxt said the transaction is designed to unlock the value of its ownership stake in Ignite while allowing Aditxt to continue operating independently as a Nasdaq-listed company, subject to continued compliance with Nasdaq listing requirements.
Aditxt originally acquired Ignite as part of its strategy to identify and advance differentiated health innovation platforms. According to the company, providing Ignite with a standalone public-company platform is expected to increase the subsidiary’s visibility and access to growth capital while highlighting the value of the asset within Aditxt’s portfolio.
Ignite Proteomics is focused on developing and commercializing functional proteomics technologies for precision oncology. Its Reverse Phase Protein Array platform is designed to directly measure protein and phosphoprotein signaling activity from tumor tissue, providing insights into tumor biology that may help support therapy selection. Unlike approaches that infer protein activity from genomic data, Ignite’s platform seeks to measure biological activity directly.
The company’s current commercial focus is breast cancer, although it intends to expand into additional tumor types and therapeutic areas over time. Ignite believes its technology could play an increasingly important role as oncology treatments continue to evolve toward targeted therapies, antibody-drug conjugates, and immunotherapies.
Following the transaction, Ignite plans to expand commercial operations, increase clinical evidence generation, and pursue collaborations with academic institutions, oncology networks, payors, and biopharmaceutical companies. Net proceeds from the transaction, including cash held in the acquisition company’s trust account and any additional financing, are expected to support these efforts.
Under the terms of the agreement, Ignite equity holders are expected to receive newly issued shares of the new holding company based on a reference price of $10 per share. Following closing, the combined company is expected to be led by Ignite’s current management team, and the board of directors is expected to consist of seven members designated by Ignite, including a majority of independent directors.
The transaction remains subject to shareholder approvals, SEC review and effectiveness of a registration statement, NYSE listing approval, regulatory requirements, and minimum financing conditions.
Ladenburg Thalmann & Co. is serving as financial advisor to the newly formed public holding company and Ignite Proteomics, while Meister Seelig & Schuster is acting as legal counsel.
KEY QUOTE:
“Today’s announcement represents an important milestone for Aditxt and Ignite. Aditxt owns 100% of Ignite, a differentiated precision oncology asset, and this transaction is expected to unlock that value through a business combination that values Ignite at approximately $150 million. At the same time, Aditxt is expected to continue as a separate Nasdaq-listed company focused on advancing its broader health innovation strategy. For Ignite, becoming an independent public company is expected to provide the focus, visibility and access to capital needed to accelerate commercialization, expand clinical evidence generation and pursue broader adoption of its functional proteomics platform in oncology.”
Jeff Busch, Interim Chief Executive Officer, Aditxt, and Chief Executive Officer, Ignite Proteomics
